International Myeloma Working Group Consensus Statement Regarding the Current Status of Allogeneic Stem-Cell Transplantation for Multiple Myeloma

被引：121
作者：
Lokhorst, Henk
Einsele, Hermann
Vesole, David
Bruno, Benedetto
Miguel, Jesus San
Perez-Simon, Jose A.
Kroger, Nicolaus
Moreau, Philippe
Gahrton, Gosta
Gasparetto, Cristina
Giralt, Sergio
Bensinger, William
机构：
[1] Univ Utrecht Hosp, Utrecht, Netherlands
[2] Univ Hosp Wuerzburg, Wurzburg, Germany
[3] Univ Hosp Hamburg Eppendorf, Hamburg, Germany
[4] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA
[5] Univ Turin, Giovanni Battista Hosp, Turin, Italy
[6] Univ Hosp Salamanca, Salamanca, Spain
[7] Ctr Hosp Univ Hotel Dieu, Nantes, France
[8] Karolinska Univ Hosp, Karolinska Inst, Stockholm, Sweden
[9] Duke Univ Hosp, Durham, NC USA
[10] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA
[11] Univ Washington, Seattle, WA 98195 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 29期
关键词：
VERSUS-HOST-DISEASE; BONE-MARROW-TRANSPLANTATION; DONOR LYMPHOCYTE INFUSIONS; IN-SITU HYBRIDIZATION; TANDEM AUTOLOGOUS TRANSPLANTATION; MINOR HISTOCOMPATIBILITY ANTIGENS; COOPERATIVE-ONCOLOGY-GROUP; NEWLY-DIAGNOSED MYELOMA; HIGH-DOSE CHEMOTHERAPY; RELAPSE-FREE SURVIVAL;
D O I：
10.1200/JCO.2010.29.7929
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Purpose To define consensus statement regarding allogeneic stem-cell transplantation (Allo-SCT) as a treatment option for multiple myeloma (MM) on behalf of International Myeloma Working Group. Patients and Methods In this review, results from prospective and retrospective studies of Allo-SCT in MM are summarized. Results Although the introduction of reduced-intensity conditioning (RIC) has lowered the high treatment-related mortality associated with myeloablative conditioning, convincing evidence is lacking that Allo-RIC improves the survival compared with autologous stem-cell transplantation. Conclusion New strategies are necessary to make Allo-SCT safer and more effective for patients with MM. Until this is achieved, Allo-RIC in myeloma should only be recommended in the context of clinical trials. J Clin Oncol 28:4521-4530. (C) 2010 by American Society of Clinical Oncology
引用
收藏
页码：4521 / 4530
页数：10
相关论文
共 107 条
  • [1] Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model
    Alici, Evren
    Konstantinidis, Kyriakos V.
    Sutlu, Tolga
    Aints, Alar
    Gahrton, Gosta
    Ljunggren, Hans-Gustaf
    Dilber, M. Sirac
    [J]. EXPERIMENTAL HEMATOLOGY, 2007, 35 (12) : 1839 - 1846
  • [2] Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation
    Atanackovic, Djordje
    Arfsten, Julia
    Cao, Yanran
    Gnjatic, Sacha
    Schnieders, Frank
    Bartels, Katrin
    Schilling, Georgia
    Faltz, Christiane
    Wolschke, Christine
    Dierlamm, Judith
    Ritter, Gerd
    Eiermann, Thomas
    Hossfeld, Dieter Kurt
    Zander, Axel R.
    Jungbluth, Achim A.
    Old, Lloyd J.
    Bokemeyer, Carsten
    Kroeger, Nicolaus
    [J]. BLOOD, 2007, 109 (03) : 1103 - 1112
  • [3] Maintenance, therapy with thalidomide improves survival in patients with multiple myeloma
    Attal, Michel
    Harousseau, Jean-Luc
    Leyvraz, Serge
    Doyen, Chantal
    Hulin, Cyrille
    Benboubker, Lofti
    Agha, Ibrahim Yakoub
    Bourhis, Jean-Henri
    Garderet, Laurent
    Pegourie, Brigitte
    Dumontet, Charles
    Renaud, Marc
    Voillat, Laurent
    Berthou, Christian
    Marit, Gerald
    Monconduit, Mathieu
    Caillot, Denis
    Grobois, Bernard
    Avet-Loiseau, Herve
    Moreau, Philippe
    Facon, Thierry
    [J]. BLOOD, 2006, 108 (10) : 3289 - 3294
  • [4] Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation
    Avet-Loiseau, H
    Facon, T
    Grosbois, B
    Magrangeas, F
    Rapp, MJ
    Harousseau, JL
    Minvielle, S
    Bataille, R
    [J]. BLOOD, 2002, 99 (06) : 2185 - 2191
  • [5] Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome
    Avet-Loiseau, Herve
    Attal, Michel
    Moreau, Philippe
    Charbonnel, Catherine
    Garban, Frederic
    Hulin, Cyrille
    Leyvraz, Serge
    Michallet, Mauricette
    Yakoub-Agha, Ibrahim
    Garderet, Laurent
    Marit, Gerald
    Michaux, Lucienne
    Voillat, Laurent
    Renaud, Marc
    Grosbois, Bernard
    Guillerm, Gaelle
    Benboubker, Lotfi
    Monconduit, Mathieu
    Thieblemont, Catherine
    Casassus, Philippe
    Caillot, Denis
    Stoppa, Anne-Marie
    Sotto, Jean-Jacques
    Wetterwald, Marc
    Dumontet, Charles
    Fuzibet, Jean-Gabriel
    Azais, Isabelle
    Dorvaux, Veronique
    Zandecki, Marc
    Bataille, Regis
    Minvielle, Stephane
    Harousseau, Jean-Luc
    Facon, Thierry
    Mathiot, Claire
    [J]. BLOOD, 2007, 109 (08) : 3489 - 3495
  • [6] Negative selection of peripheral blood stem cells to support a tandem autologous transplantation programme in multiple myeloma
    Barbui, AM
    Galli, M
    Dotti, G
    Belli, N
    Borleri, G
    Gritti, G
    Bellavita, P
    Viero, P
    Comotti, B
    Barbui, T
    Rambaldi, A
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2002, 116 (01) : 202 - 210
  • [7] Thalidomide and hematopoietic-cell transplantation for multiple myeloma
    Barlogie, B
    Tricot, G
    Anaissie, E
    Shaughnessy, J
    Rasmussen, E
    van Rhee, F
    Fassas, A
    Zangari, M
    Hollmig, K
    Pineda-Roman, M
    Lee, C
    Talamo, G
    Thertulien, R
    Kiwan, E
    Krishna, S
    Fox, M
    Crowley, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (10) : 1021 - 1030
  • [8] Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US intergroup trial S9321
    Barlogie, B
    Kyle, RA
    Anderson, KC
    Greipp, PR
    Lazarus, HM
    Hurd, DD
    McCoy, J
    Dakhil, SR
    Lanier, KS
    Chapman, RA
    Cromer, JN
    Salmon, SE
    Durie, B
    Crowley, JC
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (06) : 929 - 936
  • [9] Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3
    Barlogie, Bart
    Anaissie, Elias
    van Rhee, Frits
    Haessler, Jeffrey
    Hollmig, Klaus
    Pineda-Roman, Mauricio
    Cottler-Fox, Michele
    Mohiuddin, Abid
    Alsayed, Yazan
    Tricot, Guido
    Bolejack, Vanessa
    Zangari, Maurizio
    Epstein, Joshua
    Petty, Nathan
    Steward, Douglas
    Jenkins, Bonnie
    Gurley, Jennifer
    Sullivan, Ellen
    Crowley, John
    Shaughnessy, John D. Jr
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2007, 138 (02) : 176 - 185
  • [10] Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation
    Baron, Frederic
    Storb, Rainer
    Storer, Barry E.
    Maris, Michael B.
    Niederwieser, Dietger
    Shizuru, Judith A.
    Chauncey, Thomas R.
    Bruno, Benedetto
    Forman, Stephen J.
    McSweeney, Peter A.
    Maziarz, Richard T.
    Pulsipher, Michael A.
    Agura, Edward D.
    Wade, James
    Sorror, Mohamed
    Maloney, David G.
    Sandmaier, Brenda M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (25) : 4150 - 4157
12345678910